Denali Therapeutics Inc (NASDAQ:DNLI)
| 30.93 Delayed Data As of Jun 24 |  +0.74 / +2.45%Today’s Change | 20.24 Today|||52-Week Range 79.70 | -30.65% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.8B |
Company Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Contact Information
Denali Therapeutics, Inc. 161 Oyster Point Boulevard San Francisco California 94080 |
Employees
Shareholders
| Individual stakeholders | 51.15% |
| Mutual fund holders | 41.16% |
| Other institutional | 27.67% |
Top Executives
| Ryan J. Watts | President, Chief Executive Officer & Director |
| Alexander O. Schuth | Secretary, Chief Operating & Financial Officer |
| Carole Ho | Chief Medical Officer & Head-Development |
| Dana Andersen | CTO & Chief Manufacturing Officer |
| Joe Lewcock | Chief Scientific Officer |
